BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
(4) - EconoTimes)
CHESTERBROOK, Pa., Aug. 14, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that the independent Compensation Committee of the Board of Directors of the Company approved, effective as of July 31, August 7, and August 10, 2017, the grant of inducement stock options to purchase an aggregate of 87,000 shares of the Company’s common stock to four new employees. These awards were granted pursuant to the Trevena, Inc. Inducement Plan as an inducement material to the new employees entering into employment with the Company, in accordance with NASDAQ Listing Rule 5635(c)(4).
The first stock option grant, for 27,000 shares, has an exercise price per share of $2.61, the closing stock price on July 31, 2017. The second and third stock option grants, both for 20,000 shares, have an exercise price per share of $2.48, the closing stock price on August 7, 2017. The fourth stock option, for 20,000 shares, has an exercise price per share of $2.34, the closing stock price on August 10, 2017. Each option grant has a ten-year term and will vest with respect to one-fourth of the total number of shares subject to the option on each of first, second, third, and fourth anniversaries of the grant date.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO. Trevena also has discovered TRV250, in early clinical development for the treatment of migraine, and TRV734 for pain. The Company maintains an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Vice President, Corporate Strategy & Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
